Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.
Fujiki S, Iijima K, Okabe M, Niwano S, Tsujita K, Naito S, Ando K, Kusano K, Kato R, Nitta J, Miura T, Mitsuhashi T, Kario K, Kondo Y, Ieda M, Hagiwara N, Murohara T, Takahashi K, Tomita H, Takeishi Y, Anzai T, Shimizu W, Watanabe M, Morino Y, Kato T, Tada H, Nakagawa Y, Yano M, Maemura K, Kimura T, Yoshida H, Ota K, Tanaka T, Kitamura N, Node K, Aizawa Y, Shimizu I, Izumi D, Ozaki K, Minamino T; EMPA-ICD investigators.
Fujiki S, et al.
Diabetes Ther. 2020 Nov;11(11):2739-2755. doi: 10.1007/s13300-020-00924-9. Epub 2020 Sep 23.
Diabetes Ther. 2020.
PMID: 32968947
Free PMC article.